Biogen Inc. closed 49.79% below its 52-week high of $238.00, which the company achieved on July 12th.

Biogen’s Skyclarys (omaveloxolone) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as the ...

Biogen Netherlands has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency ...

Biogen Inc. closed 51.05% below its 52-week high of $238.00, which the company reached on July 12th.

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Skyclarys (omaveloxolone), the first treatment ...

EU authorizes Eisai-Biogen's drug for early Alzheimer's treatment ... Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain disruptions and that favorable ...

32 pharma companies demanded more favorable policies in order for them to maintain operations in the EU amid the threat of ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

This summary of health news briefs includes reports on how the U.S.-China trade war impacts drug costs, EU approval of ...